BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/13/2016 9:14:00 AM | Browse: 1209 | Download: 1856
 |
Received |
|
2016-03-05 13:21 |
|
Peer-Review Started |
|
2016-03-07 09:05 |
|
To Make the First Decision |
|
2016-03-21 09:32 |
|
Return for Revision |
|
2016-03-22 10:10 |
|
Revised |
|
2016-03-31 17:09 |
|
Second Decision |
|
2016-04-13 07:57 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2016-04-20 14:20 |
|
Articles in Press |
|
2016-04-20 14:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2016-05-25 08:14 |
|
Typeset the Manuscript |
|
2016-06-02 08:45 |
|
Publish the Manuscript Online |
|
2016-06-13 09:14 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Control Study |
| Article Title |
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Feng Xia, Li-Li Wu, Wan-Yee Lau, Hong-Bo Huan, Xu-Dong Wen, Kuan-Sheng Ma, Xiao-Wu Li and Ping Bie |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Key Laboratory of Tumor Immunology and Pathology of Ministry of Education |
2012jsz108 |
| National Natural Sciences Foundation of China |
81272224 |
|
| Corresponding Author |
Feng Xia, MD, PhD, Professor of Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, Southwest Cancer Center, Third Military Medical University, No. 30 Gaotanyanzhengjie, Chongqing 400038,
China. txzzxf@163.com
|
| Key Words |
Hepatectomy; Hepatocellular carcinoma; Sorafenib; Survival; Tumor recurrence |
| Core Tip |
Hepatocellular carcinoma (HCC) has a 5-year recurrence rate reaching 80%-90% even after potentially curative treatment. Therefore, it is extremely important to prevent recurrence for the prognosis of HCC patients. Sorafenib is the only approved treatment for patients with advanced HCC. Thus, based on the action of sorafenib, namely inhibition of tumor cell proliferation and angiogenesis, there is rationale for the study of sorafenib as an adjuvant therapy in HCC. It is essential to investigate the efficacy and safety of adjuvant sorafenib administered following curative resection in patients with Barcelona Clinic Liver Cancer-stage C HCC.
|
| Publish Date |
2016-06-13 09:14 |
| Citation |
Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(23): 5384-5392 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i23/5384.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i23.5384 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
